Dolutegravir/lamivudine/tenofovir

Source: Wikipedia, the free encyclopedia.
(Redirected from
Dolutegravir/lamivudine/tenofovir disoproxil
)
Dolutegravir/lamivudine/tenofovir
Combination of
Nucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleoside reverse transcriptase inhibitor
Clinical data
Other namesTenofovir/lamivudine/dolutegravir (TLD)
Routes of
administration
By mouth
ATC code)

Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a

tenofovir/lamivudine/efavirenz as an alternative.[2] It is taken by mouth.[3]

Side effects may include

It is on the

generic medication.[5] It is tentatively approved in the United States as of 2019, full approval is pending expiration of the US patents on dolutegravir (Tivicay) and tenofovir disoproxil (Viread).[6][7]

Medical uses

As of 2019, it is listed by the

tenofovir/lamivudine/efavirenz as an alternative.[2] It may be used in people with both HIV and tuberculosis, however if the person is on rifampicin a larger dose of dolutegravir is needed.[2]

Side effects

Side effects may include

first trimester.[2] It should not be used with dofetilide.[3]

Society and culture

Economics

In the developing world it costs about US$75 per year.[8] It is considered more cost effective than tenofovir/lamivudine/efavirenz as of 2019.[2]

References

  1. ^ a b "Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD)" (PDF). World Health Organization (WHO). Retrieved 15 November 2019.
  2. ^ . WHO/CDS/HIV/19.15; License: CC BY-NC-SA 3.0 IGO.
  3. ^ a b c d "WHO-PQ Recommended summary of product characteristics" (PDF). July 2019. Archived from the original (PDF) on November 16, 2019. Retrieved 16 November 2019.
  4. . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  5. ^ "TDF/3TC/DTG" (PDF). Retrieved 16 November 2019.
  6. ^ "NDA 209618 Tentative Approval" (PDF). U.S. Food and Drug Administration (FDA). 25 March 2019. Retrieved 16 November 2019.
  7. ^ "NDA 210796 Tentative Approval" (PDF). U.S. Food and Drug Administration (FDA). 18 August 2017.
  8. S2CID 13674631
    .

External links